Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 1308

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 11
Chunk 1308
---
.2
     
    Nominating
    and Corporate Governance Committee Charter (incorporated by reference to Exhibit 99.2 to Form S-1 filed July 28, 2023).
  
    99.3
     
    Compensation
    Committee Charter (incorporated by reference to Exhibit 99.3 to Form S-1 filed July 28, 2023).
  
    99.4
     
    Corporate
    Governance Guidelines (incorporated by reference to Exhibit 99.4 to Form S-1 filed July 28, 2023).
  
    99.5
     
    Related
    Person Transaction Policy and Procedures (incorporated by reference to Exhibit 99.6 to Form S-1 filed July 28, 2023).
  
    101.INS
     
    Inline
    XBRL Instance Document
  
    101.SCH
     
    Inline
    XBRL Taxonomy Extension Schema Document
  
    101.CAL
     
    Inline
    XBRL Taxonomy Extension Calculation Linkbase Document
  
    101.DEF
     
    Inline
    XBRL Taxonomy Extension Definition Linkbase Document
  
    101.LAB
     
    Inline
    XBRL Taxonomy Extension Label Linkbase Document
  
    101.PRE
     
    Inline
    XBRL Taxonomy Extension Presentation Linkbase Document
  
    104
     
    Cover
    Page Interactive Data File (embedded within the Inline XBRL document)

    +
     
    Denotes
    management contract or compensatory plan or arrangement.
  
    *
     
    Filed
    herewith
  
    **
     
    Furnished
    herewith
  
    #
     
    A
    signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company
    and furnished to the Securities and Exchange Commission or its staff upon request.

Item
16. Form 10-K

Summary
None.

87

MIRA
PHARMACEUTICALS, INC.

INDEX
TO FINANCIAL STATEMENTS

    Report
    of Independent Registered Public Accounting Firm (PCAOB Firm ID 106)
    F-2
  
    Report
    of Independent Registered Public Accounting Firm (PCAOB Firm ID 42)
    F-3
  
    Balance
    Sheets as of December 31, 2024 and 2023
    F